Finance Watch: Biopharma VC Funding Dips In Q3, Remains Relatively High For Year

With Exits Down, So Are New Financings

Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.

Finance Watch Private Company
• Source: Shutterstock

Venture capital investment dropped about 41% for biopharma firms for the third quarter from Q2, with 94 companies raising $4.5bn in Q3, down from 251 companies that raised $7.6bn in Q2, according to the Venture Monitor report from the National Venture Capital Association (NVCA) and Pitchbook. But despite the stark quarter-over-quarter decline, 2022 still is the third-highest VC fundraising year on record for the sector. With a year-to-date total of $23.8bn, 2022 falls behind the record-breaking years of 2020 and 2021, in which the industry raised $28.7bn and $38bn, respectively.

The biopharmaceutical industry experience is consistent with VC trends across all industries. Overall, investment declined by almost 20% across all...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.